Company Profile

Profile last edited on: 6/30/16      CAGE: 46R59      UEI:

Business Identifier: Facilitating cell platform technology (FCRx): enabling Immunosuppression-Free Transplants
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

201 East Jefferson Street Suite 11
Louisville, KY 40202
   (502) 569-1059
Location: Single
Congr. District: 03
County: Jefferson

Public Profile

Regenerex, LLC is focused to facilitating cell platform technology. (FCRx) widely available to treat many disorders with unmet need. The FCRx product eliminates the need for a perfectly matched donor, thereby allowing nearly any candidate for a stem cell transplant to receive the treatment. Hematopoietic stem cell transplantation (HSCT) has been used to successfully treat inherited metabolic enzyme disorders, red blood cell disorders (sickle cell disease and thalassemia), to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company’s proprietary FCRx platform therapy: The hematopoietic stem cell-based immunological tolerance protocol is in the final stages of a successful FDA Phase II clinical trial in living donor kidney transplant recipients that has resulted in graft survival without the need for lifelong immunosuppression. In 2013 Regenerex formed a worldwide exclusive partnership with Novartis to make the FCRx cellular product widely available. This collaboration reaffirms the Novartis commitment to transplantation. Beyond transplant, Regenerex’s novel platform potentially has curative potential for multiple diseases with unmet need and will be investigated in the rescue of serious genetic deficiencies such as inherited metabolic storage disorders and hemoglobinopathies. “As the field of biomedicine sits on the cusp of a new transformation, we are excited to announce this agreement which supports the Novartis leadership position in cell therapy,” said Dr. Timothy Wright, Global Head Development, Novartis Pharmaceuticals. “Thirty years ago, Novartis developed ciclosporin, which changed transplantation treatment paradigms and enabled countless lives to be saved. Now, this collaboration, along with our internal cell therapy assets, has the potential to transform medicine once again through innovation.” As a result potentially millions suffering from a number of disorders could benefit. Regenerex has also established a novel strategic public/private partnership with the University of Louisville’s Institute for Cellular Therapeutics to expedite translation of discoveries form bench to bedside. Corporate and University scientists work together to manufacture the FCRx product and study the mechanism of action of the Facilitating Cell’s functions in this unique translational researc

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency